For the year ending 2025-12-31, REVBW had $4,201,313 increase in cash & cash equivalents over the period.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | -8,913,649 |
| Stock-based compensation expense | 595,368 |
| Depreciation expense | 27,058 |
| Non-cash lease expense | 18,630 |
| Loss on disposal of equipment | -11,207 |
| Change in fair value of warrant liability | -2,158 |
| Prepaid expenses and other current assets | 44,598 |
| Other assets | 30,941 |
| Accounts payable | -206,120 |
| Accrued expenses | 269,756 |
| Operating lease liability | 5,866 |
| Net cash used in operating activities | -8,269,581 |
| Proceeds from public offering, net-May2025Public Offering | 3,388,244 |
| Proceeds from warrant exercise-Class HPre Funded Warrants | 297 |
| Proceeds from warrant exercise-Class HCommon Stock Warrants | 363,000 |
| Proceeds from warrant exercise-Warrant Inducement | 8,719,353 |
| Net cash provided by financing activities | 12,470,894 |
| Net increase (decrease) in cash and cash equivalents | 4,201,313 |
| Cash and cash equivalents at beginning of period | 6,499,018 |
| Cash and cash equivalents at end of period | 10,700,331 |
REVELATION BIOSCIENCES, INC. (REVBW)
REVELATION BIOSCIENCES, INC. (REVBW)